NervGen Pharma Corporation (QB) (NGENF)

NervGen Pharma to Present at Unite2Fight Paralysis’ 20th Annual Science and Advocacy Symposium

Adam Rogers, MD, President and Chief Executive Officer of NervGen to present and discuss clinical data from the...

NervGen Pharma Appoints Adam Rogers as Chief Executive Officer to Continue Leading the Company’s Growth and Execution of Its Mission in Spinal Cord Injury

VANCOUVER, British Columbia, Feb. 09, 2026 (GLOBE NEWSWIRE) -- NervGen Pharma Corp. (“NervGen” or the...

NervGen Pharma to Ring the Nasdaq Closing Bell on January 22, 2026, Celebrating Its Recent Nasdaq Listing

VANCOUVER, British Columbia, Jan. 20, 2026 (GLOBE NEWSWIRE) -- NervGen Pharma Corp. (“NervGen” or the...

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

NervGen Pharma Begins Trading on Nasdaq Today

VANCOUVER, British Columbia, Jan. 08, 2026 (GLOBE NEWSWIRE) -- NervGen Pharma Corp. (“NervGen” or the...

Form EFFECT - Notice of Effectiveness

Form CERT - Certification by an exchange approving securities for listing

Form 8-A12B - Registration of securities [Section 12(b)]

Form F-10/A - Registration Statement for Securities of certain Canadian Issuers.: [Amend]

Form F-X - Appointment of Agent for Service of Process and Undertaking

Form F-10 - Registration Statement for Securities of certain Canadian Issuers.

Amended Small Company Offering and Sale of Securities Without Registration (d/a)

x NoneEntity Type0001751912  x Corporation o Limited Partnership o Limited Liability Company o General Partnership o Business...

Small Company Offering and Sale of Securities Without Registration (d)

x NoneEntity Type0001751912  x Corporation o Limited Partnership o Limited Liability Company o General Partnership o Business...

Amended Small Company Offering and Sale of Securities Without Registration (d/a)

x NoneEntity Type0001751912  x Corporation o Limited Partnership o Limited Liability Company o General Partnership o Business...